Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.

Saved in:
Bibliographic Details
Title: Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
Authors: Nikolcheva T; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland. Electronic address: tania.nikolcheva@roche.com., Pagano G; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F Hoffmann-La Roche, Basel, Switzerland; University of Exeter Medical School, London, UK., Anzures-Cabrera J; Roche Products, Welwyn Garden City, UK., Trundell D; Roche Products, Welwyn Garden City, UK., Kustermann T; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F Hoffmann-La Roche, Basel, Switzerland., Simuni T; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Marek K; Institute for Neurodegenerative Disorders, New Haven, CT, USA., Pavese N; Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK., Seppi K; Department of Neurology, Medical University Innsbruck, Innsbruck, Austria., Stocchi F; Department of Neurology, University San Raffaele Roma and the Institute for Research and Medical Care, IRCCS San Raffaele Pisana, Rome., Postuma RB; Department of Neurology, McGill University, Montreal, QC, Canada; Montreal Neurological Institute, Montreal, QC Canada., Pross N; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland., Monnet A; Product Development Data Science, F Hoffmann-La Roche, Basel, Switzerland., Respondek G; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland., Schlegel V; Product Development Safety, F Hoffmann-La Roche, Basel, Switzerland., Boak L; Global Product Strategy, F Hoffmann-La Roche, Basel, Switzerland., Rutten-Jacobs L; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland., Kerchner GA; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland., Brundin P; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F Hoffmann-La Roche, Basel, Switzerland., Svoboda H; Global Product Strategy, F Hoffmann-La Roche, Basel, Switzerland., Bonni A; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F Hoffmann-La Roche, Basel, Switzerland.
Corporate Authors: PADOVA Investigators, Prasinezumab Study Group
Source: Lancet (London, England) [Lancet] 2026 May 30; Vol. 407 (10544), pp. 2227-2240.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(26)00865-2